malignant genital tumors benign gynecologic tumors
Conditions
Interventions
measuring urine-blood porphyrin concentration using oral 5-aminolevulinic acid(300mg) 1)50cases, for 3 years Pre-operative patients with malignant including ovarian cancer, cervical cancer, endometr
Sponsors
Nagoya University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1: >=20 years old Japanese 2: Performance Status 0-1 3: A person who has obtained consent under the voluntary 4: After screening gynecological
Exclusion criteria
Exclusion criteria: 1)Patients (including tuberculosis activities) uncontrolled infection. 2)Patients with severe anamnesis (Malignant hypertension. With severe congestive heart failure. Severe liver failure. Myocardial infarction within 3 months. End-stage cirrhosis. Poorly controlled diabetes. Severe pulmonary fibrosis. Interstitial pneumonia activity) 3) Allogeneic bone marrow transplantation 4) Patients with severe mental disorders 5)Patients with porphyria or hypersensitivity to porphyrins allergy 6) A gravida, a lactational woman 7) Patients with severe anemia 8)Patients were deemed inappropriate by research investigators 9)Patients with malignant tumor during treatment. cancer patients within 5 years after treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relation between of urinary/serum porphyrins value and pathological factors in 3 groups (patients with malignant genital tumor, with benign tumor, healty person) . Receiver operating characteristic (ROC) curves are constructed for porphyrins, and the cut-off value to identify malignant tumor. | — |
Countries
Japan
Contacts
Public ContactMika Mizuno
Nagoya University Graduate School of Medicine Department of Obstetrics and Gynecology
Outcome results
None listed